Login to Your Account

Oxyrane Brings in $26.5M to Fund Pompe's Drug R&D

By Nuala Moran
BioWorld Today Correspondent

Friday, November 18, 2011
LONDON – Oxyrane Ltd. has raised $26.5 million in a fourth private round as it prepares to move its first enzyme replacement therapy into clinical development for the treatment of Pompe's disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription